Products - Children and teenagers | Topic

Showing 19 products

Date | Title

Status: In developmentRemove ‘Status: In development’ filter

Digital therapy for chronic tic disorders and Tourette syndrome: early value assessment
Status:
In development
Programme:
Health technology evaluation
Expected publication date:
7 May 2025
Somapacitan for treating growth hormone deficiency in people 3 to 17 years [ID6178]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
29 May 2025
Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
25 June 2025
Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people aged 6 years and over [ID6372]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
21 August 2025
Digital self-help for people with eating disorders: early value assessment
Status:
In development
Programme:
Health technology evaluation
Expected publication date:
13 November 2025
School-based interventions: physical and mental health and wellbeing promotion
Status:
In development
Expected publication date:
TBC
VTS-270 for treating Niemann-Pick type C1 [ID1267]
Status:
In development
Programme:
Highly specialised technologies guidance
Expected publication date:
TBC
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Omburtamab for treating relapsed neuroblastoma [ID1664]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Leriglitazone for treating andrenoleukodystrophy [ID3903]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nintedanib for treating fibrosing interstitial lung disease in people aged 6 to 17 [ID6194]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (MA review of HST12) [ID6145]
Status:
In development
Programme:
Highly specialised technologies guidance
Expected publication date:
TBC
Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years ID3897
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Vosoritide for treating achondroplasia in people 4 months and over ID6488
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over TSID 10632
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Soticlestat for treating seizures associated with Dravet syndrome in people 2 years and over TSID 12091
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC

What we do

Into practice

Who we are

Children and teenagers Products

Showing 19 products

Digital therapy for chronic tic disorders and Tourette syndrome: early value assessment

Somapacitan for treating growth hormone deficiency in people 3 to 17 years [ID6178]

Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]

Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people aged 6 years and over [ID6372]

Digital self-help for people with eating disorders: early value assessment

School-based interventions: physical and mental health and wellbeing promotion

VTS-270 for treating Niemann-Pick type C1 [ID1267]

Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]

Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]

Omburtamab for treating relapsed neuroblastoma [ID1664]

Leriglitazone for treating andrenoleukodystrophy [ID3903]

Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]

Nintedanib for treating fibrosing interstitial lung disease in people aged 6 to 17 [ID6194]

Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (MA review of HST12) [ID6145]

Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years ID3897

Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427]

Vosoritide for treating achondroplasia in people 4 months and over ID6488

Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over TSID 10632

Soticlestat for treating seizures associated with Dravet syndrome in people 2 years and over TSID 12091

Quality standards

Indicators

Get support from NICE

Learn how we evaluate technologies

Register your product

Find published and proposed evaluations

Our programmes

Get involved

What we do

Into practice

Who we are

Children and teenagers Products

Showing 19 products